Rozlytrek (Entrectinib) is a kinase inhibitor used for the Treatment of:
- ROS1-Positive Non-Small Cell Lung Cancer
- NTRK Gene Fusion-Positive Solid Tumors
Dosage: The recommended entrectinib dose for patients with ROS1-positive non-small cell lung cancer and NTRK gene fusion-positive solid tumors is 600 mg orally once daily with or without food until the disease is progressive or unacceptable toxicity is noticed. Swallow the entrectinib capsules whole. Do not open, crush, chew, or dissolve the contents of the capsule. In case of missed dose, patients are instructed to make up that dose unless the next dose is due within 12 hours. If vomiting occurs promptly after taking a dose, patients are instructed to repeat that dose.
Side Effects: The most commonly reported entrectinib side effects include:
- Cognitive impairment
- Increased weight
- Vision disorders
Warnings and Precautions:
- Patients should be assessed for left ventricular ejection fraction (LVEF) before initiation of entrectinib with symptoms or known risk factors for CHF.
- Patients with entrectinib should be monitored for liver tests, including ALT and AST, every 14 days during the first month of therapy, then monthly thereafter.
- Patients should be assessed for serum uric acid levels prior to starting therapy with entrectinib capsules and periodically while on treatment.
- Patients with entrectinib treatment should be monitored for signs and symptoms of hyperuricemia. Use of entrectinib may cause fetal harm if administered to a pregnant woman.
- Females are advised not to breastfeed during treatment with rozlytrek capsules and for one week after the final dose.